Clinical trials remain one of the most resource-intensive stages of drug development. Slow enrollment, protocol amendments, zero-enrollment sites, and incomplete real-world evidence can delay timelines and increase cost—ultimately slowing access to life-changing therapies for patients who need them most.
Today, we are excited to introduce Truveta’s new clinical trials offering that empowers trial sponsors to design, optimize, and execute studies with the most complete, timely real-world data available in the United States. Built in collaboration with our health system members, this new solution provides unprecedented visibility into providers and sites—updated daily—to support every stage of clinical development.
Real-time trial design and optimization
Truveta’s clinical trials offering is powered by longitudinal EHR data enriched with notes and images, linked with closed claims and social drivers of health. Unlike traditional retrospective data sources, Truveta Data is refreshed daily, enabling real-time insights that help sponsors plan and adapt their trials with confidence.
With this level of precision and timeliness, sponsors can model feasibility, refine complex eligibility criteria, evaluate endpoints, and predict enrollment dynamics—all before a trial launches. Once a study is live, teams can continuously monitor recruitment, site performance, and patient availability as conditions evolve.
Accelerate enrollment with precision
Finding patients who meet evolving trial criteria—and reaching the clinicians who care for them—has historically been a challenge. Truveta solves this by providing:
- Real-time eligibility identification, including for rare disease and late-stage trials
- Granular, complete EHR data, including clinical notes and images, linked to claims and social drivers of health
- Provider- and site-level visibility to prioritize trial-ready investigators
- Connectivity to a nationwide network of leading US health systems to uncover new recruitment and data collection opportunities
With these capabilities, sponsors can accelerate enrollment and engage investigators earlier and more effectively, enabling access to patients who might benefit most from these new therapies.
De-risk and optimize every stage
Clinical trials are often disrupted by costly amendments or underperforming sites. Truveta’s clinical trials solution helps prevent these issues through:
- Dynamic feasibility modeling to reduce zero-enrollment sites and avoid protocol pitfalls
- Real-time cohort design using computable phenotypes and temporality to instantly assess expanded eligibility
- Daily refreshed data to track enrollment, patient movement, and site performance throughout the study
This continuous visibility reduces the risk of under-enrollment, protocol amendments, and underperforming sites, allowing teams to adapt quickly as new information emerges.
Maximize trial utility with continuous evidence generation
Truveta Data is linkable to registries, sites, or trial participants, enabling ongoing follow-up and long-term evidence generation. Sponsors can:
- Conduct prospective research with linked data and continuous updates
- Track outcomes, safety, and adherence beyond enrollment for post-market and label-expansion studies
- Build regulatory-grade external control arms and single-arm, real-world studies using longitudinal real-world data
The result is a more complete evidence package that supports development, approval, and commercialization by generating regulatory-grade evidence from feasibility and protocol design through post-market commitments.
Advance discovery and improve care
With these new capabilities, sponsors can design smarter studies, enroll patients faster, and generate the robust evidence needed to bring safer, more effective therapies to patients—more efficiently than ever before.